Option chain shows key data for Livzon Pharmaceutical Gr's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Livzon Pharmaceutical Gr.

Livzon Pharmaceutical Gr (OTC:LVZPF) Stock, Option Chain

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in PRC which is pharmaceutical manufacturing.

LIVZON PHARMACEUTICAL GRP by Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc

Joe Fisher has been appointed to the role of Chief Investment Officer in addition to his roles as President and Chief Financial Officer.

News

Management

UDR Promotes Mike Lacy To COO; Plans To Initiate An Executive Search Process To Recruit  New CFO

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 6.38% on an annualized basis producing an average annual return of 17.58%. Currently, UnitedHealth Group has a market capitalization of $464.29 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 10 years ago, it would be worth $510.02 today based on a price of $504.51 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735852508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) announced its Q2 earnings on Thursday, January 2, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Lifecore Biomedical beat estimated earnings by 19.0%, reporting an EPS of $-0.25 versus an estimate of $-0.31.
Revenue was up $2.41 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company missed on EPS by $0.07 in the last quarter, resulting in a 14.000000000000002% increase share price change the following day.

To track all earnings releases for Lifecore Biomedical <a href="https://www.benzinga.com/quote/LFCR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

LFCR

Lifecore Biomedical Earnings Report: Q2 Overview

Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) reported its Q2 earnings results on Thursday, January 2, 2025 at 04:10 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Resources Connection beat estimated earnings by 0.18%, reporting an EPS of $0.18 versus an estimate of $0.0.
Revenue was down $17.51 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company missed on EPS by $0.03 in the last quarter, resulting in a 12.0% drop share price change the following day.
Here's a look at Resources Connection's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.07</td>
<td>0.05</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>0.28</td>
<td>0.17</td>
<td>0.28</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>137.92M</td>
<td>140.60M</td>
<td>152.77M</td>
<td>161.94M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>136.94M</td>
<td>148.20M</td>
<td>151.31M</td>
<td>163.13M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Resources Connection <a href="https://www.benzinga.com/quote/RGP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Resources Connection Q2 Earnings

WIIM

CHEK

Check-Cap shares are trading higher after the company announced it was granted European Patent Number EP4087488 titled "RADIATION CAPSULE FOR BOWEL DISEASE IMAGING AND LOCALIZE DRUG DELIVERY".

Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of undefined by Infinity percent. The company reported quarterly sales of $145.60 million which beat the analyst consensus estimate of $137.02 million by 6.26 percent. This is a 10.74 percent decrease over sales of $163.13 million the same period last year.

Earnings Beats

Resources Connection Q2 2025 Adj EPS $0.18 Beats $0 Estimate, Sales $145.60M Beat $137.02M Estimate

SPSC

Sps Commerce Announces It Has Reached An Agreement To Acquire CARBON6 Technologies, Inc; Terms Not Disclosed

Yum! Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), the parent company of <a href="https://www.benzinga.com/general/restaurants">KFC, Pizza Hut and Taco Bell</a>, is nearing a potential <a href="https://www.benzinga.com/topic/golden-cross">Golden Cross</a>, a bullish technical indicator that could signal a turnaround for the stock.
While the stock is down 3.9% in the past month, recent upgrades and growth initiatives could bring renewed momentum to the stock.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="492" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02083745/Screenshot-2025-01-02-at-5.51.03-PM.png" alt="" class="wp-image-715166" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02083745/Screenshot-2025-01-02-at-5.51.03-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02083745/Screenshot-2025-01-02-at-5.51.03-PM-300x235.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010225&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">YUM Stock Chart Has Mixed Signals, As Golden Cross Looms</h2>
At $134.16, YUM stock sits just below key moving averages, creating a mixed technical picture:
<ul>
<li>Eight-day SMA: A bullish signal at $133.81, indicating slight upward momentum.</li>
<li>20-day, 50-day and 200-day SMAs: All hovering above the current price, signaling bearish conditions.</li>
<li>MACD: At a negative 0.55, it reinforces a bearish sentiment.</li>
<li>RSI: A neutral 46.54 suggests neither overbought nor oversold conditions.</li>
</ul>
However, the eight-day SMA edging above the price hints at brewing buying pressure, while a looming Golden Cross—where the 50-day SMA crosses above the 200-day SMA—could ignite bullish enthusiasm.
Read Also: <a href="https://www.benzinga.com/24/12/42679687/mcdonalds-evangelion-collaboration-advert-catches-elon-musks-eye-heres-what-the-techno-king-shared">McDonald&#8217;s Evangelion Collaboration Advert Catches Elon Musk&#8217;s Eye. Here&#8217;s What The Techno King Shared</a>
<h2 class="wp-block-heading">YUM Stock Investors: What To Watch</h2>
For YUM stock investors, the potential Golden Cross could serve as a signal to ride Yum's recovery wave, particularly with Argus projecting long-term earnings growth of 10%. If momentum continues, YUM stock might finally break past its resistance levels and begin its climb toward the $155 target.
While bears remain skeptical, citing mixed short-term signals, Yum's blend of technical potential and fundamental optimism is worth watching. 
Will the Golden Cross be the catalyst Yum needs? Investors might not have to wait much longer to find out.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42702291/fast-food-robots-smaller-stores-wholesale-clubs-retail-trends-for-2025">Fast-Food Robots, Smaller Stores, Wholesale Clubs: 2025 Retail Trends To Watch</a></li>
</ul>
Photo: Shutterstock

Technicals

Restaurants

Signals

General

Yum! Brands Nears Golden Cross As Investors Look For Bullish Signs

Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. The company reported quarterly sales of $32.60 million which beat the analyst consensus estimate of $29.75 million by 9.59 percent. This is a 8.13 percent increase over sales of $30.15 million the same period last year.

Lifecore Biomedical Q2 2025 GAAP EPS $(0.25) Beats $(0.29) Estimate, Sales $32.60M Beat $29.75M Estimate

PINE

Alpine Income Property Trust Acquires Lowe's Home Improvement For $22.5M

<h3>Gainers</h3>
<ul>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) stock increased by 23.5% to $0.05 during Thursday's pre-market session. The company's market cap stands at $28.5 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock increased by 21.01% to $0.99. The company's market cap stands at $2.5 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) stock moved upwards by 18.09% to $2.48. The market value of their outstanding shares is at $7.0 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares increased by 15.63% to $2.81. The market value of their outstanding shares is at $127.3 million. </li>
<li>Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) stock increased by 13.87% to $0.45. The market value of their outstanding shares is at $18.0 million. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares increased by 13.33% to $0.34. The market value of their outstanding shares is at $12.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) stock decreased by 10.4% to $0.95 during Thursday's pre-market session. The market value of their outstanding shares is at $15.7 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares declined by 8.41% to $0.4. The market value of their outstanding shares is at $20.4 million. </li>
<li>JX Luxventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock fell 7.49% to $0.99. The market value of their outstanding shares is at $6.0 million. </li>
<li>ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) shares decreased by 7.31% to $14.73. The market value of their outstanding shares is at $332.4 million. </li>
<li>Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares decreased by 6.35% to $3.1. The company's market cap stands at $130.8 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares fell 5.97% to $0.52. The company's market cap stands at $7.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIEV

AMBO

EZGO

FFIE

PNST

SVMH

TKLF

VEEE

ZSPC

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares moved upwards by 228.8% to $0.92 during Thursday's pre-market session. The market value of their outstanding shares is at $19.1 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares moved upwards by 136.44% to $1.09. The company's market cap stands at $9.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock rose 26.79% to $3.88. The company's market cap stands at $32.8 million. </li>
<li>MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) shares increased by 25.5% to $23.13. The company's market cap stands at $772.9 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock rose 23.59% to $0.21. The market value of their outstanding shares is at $23.2 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares moved upwards by 18.49% to $0.67. The market value of their outstanding shares is at $41.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares decreased by 82.1% to $1.9 during Thursday's pre-market session. The company's market cap stands at $306.9 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares decreased by 43.43% to $4.3. The company's market cap stands at $153.8 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 12.49% to $0.23. The company's market cap stands at $8.3 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares decreased by 11.88% to $2.45. The market value of their outstanding shares is at $64.8 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares decreased by 11.3% to $3.14. The market value of their outstanding shares is at $42.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 10.46% to $0.77. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BDMD

CALC

CBUS

CRIS

CTCX

NMRA

PASG

REVB

VINC

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock increased by 54.4% to $3.69 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>SKK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) shares moved upwards by 17.17% to $1.16. The company's market cap stands at $18.1 million. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock moved upwards by 15.55% to $1.56. The company's market cap stands at $20.5 million. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares rose 12.7% to $2.04. The company's market cap stands at $10.8 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares rose 11.93% to $0.28. The market value of their outstanding shares is at $5.6 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares increased by 11.84% to $0.51. The market value of their outstanding shares is at $13.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) shares fell 28.6% to $3.5 during Thursday's pre-market session. The company's market cap stands at $50.2 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) stock declined by 11.75% to $2.82. The market value of their outstanding shares is at $7.0 million. </li>
<li>Moog (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOG#NYSE">MOG</a>) shares declined by 10.77% to $174.01. The market value of their outstanding shares is at $5.8 billion. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares declined by 10.53% to $1.96. The company's market cap stands at $700.7 million. </li>
<li>Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) shares fell 9.81% to $0.92. The company's market cap stands at $134.3 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) stock decreased by 8.48% to $0.91. The market value of their outstanding shares is at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EFSH

GLXG

LNKS

OPTT

POLA

RYDE

SIDU

XPON

ZCAR

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) shares increased by 44.1% to $1.96 during Thursday's pre-market session. The market value of their outstanding shares is at $20.5 million. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) stock moved upwards by 30.08% to $4.0. The market value of their outstanding shares is at $34.8 million. </li>
<li>MicroCloud Hologram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) stock increased by 26.25% to $6.22. The company's market cap stands at $127.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock increased by 24.2% to $4.67. The company's market cap stands at $46.5 million. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) stock rose 22.23% to $0.79. The company's market cap stands at $111.0 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock moved upwards by 20.91% to $1.85. The company's market cap stands at $154.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares decreased by 8.6% to $0.89 during Thursday's pre-market session. The company's market cap stands at $33.7 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) stock declined by 8.55% to $0.63. The market value of their outstanding shares is at $22.3 million. </li>
<li>Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) stock declined by 7.63% to $3.03. The company's market cap stands at $116.0 million. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) stock fell 7.0% to $3.19. The company's market cap stands at $29.9 million. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock declined by 5.98% to $0.92. The market value of their outstanding shares is at $7.8 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares fell 5.18% to $1.1. The market value of their outstanding shares is at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

BNAI

BTOG

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

INUV

MLGO

SatixFy Communications Ltd. Ordinary Share

SATX

SOBR

TZUP

VERI

VRME

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

Dividends

Bank OZK Increases Quarterly Dividend From $0.41 To $0.42

Biotech

Check-Cap Ltd. Receives Decision To Grant European Patent Number EP4087488 titled "RADIATION CAPSULE FOR BOWEL DISEASE IMAGING AND LOCALIZE DRUG DELIVERY"

In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team.

GeneDx Appoints Bryan Dechairo As COO, Effective Immediately

In the latest quarter, 24 analysts provided ratings for Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $92.96, a high estimate of $120.00, and a low estimate of $80.00. This current average has increased by 3.08% from the previous average price target of $90.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1735851665_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Uber Technologies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Mollins</td>
<td>Gordon Haskett</td>
<td>Announces</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$114.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jairam Nathan</td>
<td>Daiwa Capital</td>
<td>Announces</td>
<td>Neutral</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Uber Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Uber Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Uber Technologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UBER/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Uber Technologies analyst ratings.</a>
<h2>Discovering Uber Technologies: A Closer Look</h2>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing technology. Uber operates in more than 70 countries, with more than 161 million users who order rides or food at least once a month.
<h3>Understanding the Numbers: Uber Technologies's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Uber Technologies's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.4%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Uber Technologies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.35%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 19.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Uber Technologies's ROA stands out, surpassing industry averages. With an impressive ROA of 5.89%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Uber Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

UBER

24 Analysts Assess Uber Technologies: What You Need To Know

Throughout the last three months, 23 analysts have evaluated Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">14</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $229.83, a high estimate of $278.00, and a low estimate of $195.00. This upward trend is apparent, with the current average reflecting a 15.87% increase from the previous average price target of $198.36.
<img src="https://www.benzinga.com/files/images/story/2025/1735851654_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Fiserv among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$239.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ole Slorer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$258.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$238.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$231.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$278.00</td>
<td>-</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$232.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$244.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$222.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$224.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$227.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Trevor Williams</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$230.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Brad Handler</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$195.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ole Slorer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fiserv. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fiserv compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Fiserv's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Fiserv's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fiserv analyst ratings.</a>
<h2>Delving into Fiserv's Background</h2>
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for us banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.
<h3>Financial Insights: Fiserv</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Fiserv showcased positive performance, achieving a revenue growth rate of 7.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Fiserv's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Fiserv's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.65%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Fiserv's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.92.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

23 Analysts Assess Fiserv: What You Need To Know

In the last three months, 6 analysts have published ratings on Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $301.5, a high estimate of $349.00, and a low estimate of $245.00. This current average has increased by 10.04% from the previous average price target of $274.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1735851643_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Vulcan Materials among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trey Grooms</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Adrian Huerta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$349.00</td>
<td>-</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Adrian Huerta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vulcan Materials. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vulcan Materials compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vulcan Materials's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Vulcan Materials's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vulcan Materials analyst ratings.</a>
<h2>All You Need to Know About Vulcan Materials</h2>
Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2023, Vulcan sold 234.3 million tons of aggregates, 13.4 million tons of asphalt mix, and 7.5 million cubic yards of ready-mix. As of Dec. 31, 2022, the company had nearly 16 billion tons of aggregates reserves.
<h3>Vulcan Materials: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3 months period, Vulcan Materials faced challenges, resulting in a decline of approximately -8.32% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Vulcan Materials's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 10.36%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vulcan Materials's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.67%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Vulcan Materials's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.45%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Vulcan Materials's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Vulcan Materials Stock: Analyst Perspectives (6 Ratings)

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group successfully held its 2024 Third Extraordinary General Me...

Livzon Pharmaceutical's Resolutions Passed at Key Meeting

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has outlined the composition of its board of directors, i...

Livzon Pharmaceutical Reveals Board Structure and Focus

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has announced an extraordinary general meeting set for De...

Livzon Pharmaceutical to Discuss A Share Repurchase Plan

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group Inc. is set to hold its 2024 second class meeting of H Sh...

Livzon Pharmaceutical Plans A Share Repurchase Strategy

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has announced a proposed plan to repurchase a portion of ...

Livzon Pharmaceutical Plans Significant A Share Buyback

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has entered into a Patent and Technology Transfer Agreeme...

Livzon Pharmaceutical Partners on Influenza Vaccine Development

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group announced that all proposed resolutions were passed durin...

Livzon Pharmaceutical Resolutions Passed in Key Meetings

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has announced a change in leadership with the resignation...

Livzon Pharmaceutical Appoints New Company Secretary

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has approved two significant agreements with Livzon MAB f...

Livzon Pharmaceutical's 2025 Deals with Livzon MAB Unveiled

Livzon Pharmaceutical Group (HK:1513) has released an update. Livzon Pharmaceutical Group has announced a series of framework agreements with its c...

Comments

Livzon Pharmaceutical Gr

Livzon Pharmaceutical Gr (LVZPF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga